Form 4: Evolus CMO Sells Shares Post-PSU Vesting

Evolus Chief Medical Officer Rui Avelar sold shares to cover tax obligations following the vesting of performance restricted stock units.

Summary

• Rui Avelar, Chief Medical Officer and Head of Research & Development at Evolus, Inc. (EOLS), acquired 8,804 shares of common stock on March 16, 2026, at a price of $0, resulting from the vesting and settlement of performance restricted stock units (PSUs).
• These PSUs were part of a grant of 17,606 PSUs at target on February 7, 2024, which were subject to performance conditions based on the Issuer's 2024 and 2025 fiscal year revenue and non-GAAP operating profit.
• The Compensation Committee certified 100% achievement of the performance conditions, leading to 17,606 earned PSUs, with 50% (8,804 shares) vesting and settling on March 16, 2026.
• On March 17, 2026, Mr. Avelar disposed of 29,996 shares of common stock at a weighted average sale price of $4.8883 per share.
• These sales were executed under a Rule 10b5-1 trading plan and were specifically to cover tax withholding obligations related to the vesting and settlement of multiple PSU and restricted stock unit awards.
• Following these transactions, Mr. Avelar beneficially owns 430,542 shares of common stock directly.
• An additional 8,802 PSUs remain outstanding and are scheduled to vest on February 7, 2027, contingent on continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The 100% achievement of PSU performance conditions is positive, but the subsequent sale of shares for tax withholding is a routine, non-discretionary transaction that does not reflect a change in company fundamentals or management's confidence.

Positives

• The Compensation Committee certified 100% achievement of the performance conditions for the PSUs, indicating strong performance against pre-specified revenue and non-GAAP operating profit targets for fiscal years 2024 and 2025.

Negatives

• The disposition of 29,996 shares by a key executive, even for tax purposes, reduces the insider's direct equity stake in the company.

Future Outlook

The remaining 8,802 performance restricted stock units (PSUs) are scheduled to vest on February 7, 2027, contingent upon the reporting person's continued service to the company.

Management Comments

• The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
• The sales represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of multiple PSU and restricted stock unit awards.

Industry Context

StockSavvy.ai notes that insider transactions, particularly sales for tax withholding purposes following equity award vesting, are common and often pre-planned under Rule 10b5-1. While they reduce an insider's direct stake, such routine transactions typically do not signal a change in management's outlook or company fundamentals, unlike discretionary sales.

Stakeholder Impact

• Shareholders: The sale of shares by a key executive, even for tax purposes, slightly dilutes the insider's direct ownership, but the transaction is routine and pre-planned, minimizing any negative signal.
• Employees: The vesting of PSUs and achievement of performance targets could be seen as positive reinforcement of the company's performance and compensation structure.

Next Steps

• The remaining 8,802 PSUs are scheduled to vest on February 7, 2027, subject to continued service.

Key Dates

Recommendation

This Form 4 details a routine insider transaction involving the vesting of performance-based equity awards and a subsequent sale of shares to cover tax obligations under a Rule 10b5-1 plan. Such transactions are common and pre-planned, typically not indicative of a change in the company's fundamental outlook or management's confidence. Therefore, a 'hold' recommendation is appropriate as this filing does not present new information that would warrant a change in investment thesis.

Keywords

Evolus, EOLS, Form 4, Insider Transaction, Performance Restricted Stock Units, PSU, Executive Compensation, Stock Sale, Tax Withholding, Rule 10b5-1